Takeda and Amylin formally end rocky global alliance for obesity
This article was originally published in Scrip
Executive Summary
Takeda and Amylin Pharmaceuticals have decided formally to end their October 2009 global agreement for the co-development and co-commercialization of compounds for obesity.